A non-peptide small molecule studied around NNMT, NAD+ and metabolic signaling — available only after a licensed provider reviews your history and decides whether it is appropriate.
Not currently offered
You are on the list. We will email you if 5-Amino-1MQ becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
5-Amino-1MQ isn't offered through Promise's prescriber network yet. Join the waitlist and we'll tell you when it is.
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A real person goes through your history and takes the time to get it right before anything is decided.
If a treatment isn't right for your history, you'll hear that plainly. That review is the whole point.
Made for your prescription by a licensed U.S. pharmacy and shipped in temperature-safe packaging.
Your care team checks in after it arrives. Adjust with your provider, or cancel at any time.
5-Amino-1MQ is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
5-Amino-1MQ is studied as an inhibitor of NNMT, an enzyme connected to nicotinamide and methyl-donor metabolism.
The direct research is largely in cells and animal models; human clinical outcomes and long-term safety remain uncertain.
A provider weighs the thin human evidence, metabolic history, medicines and the reason for the request before deciding.
5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase, usually shortened to NNMT. It is not a peptide. Most of the direct evidence comes from cells and animal models, not human clinical trials, which makes the evidence boundary the most important fact on the page. 5-Amino-1MQ is not FDA-approved.
NNMT is an enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. That places the enzyme near two large metabolic systems: nicotinamide and NAD+ salvage on one side, and methyl-donor chemistry on the other. Researchers study whether changing NNMT activity can alter energy handling in adipose tissue and liver.
5-Amino-1MQ was developed as a membrane-permeable small-molecule NNMT inhibitor. The name may circulate beside peptide products, but chemistry and evidence should not be collapsed into one category. Its oral capsule format follows from small-molecule design, not from peptide delivery.
A foundational mouse study of 5-Amino-1MQ and related NNMT inhibitors examined adipose tissue, body weight, fat mass and metabolic markers in diet-induced obesity. A later mouse pharmacology study measured body composition, glucose handling, liver findings and route-dependent exposure. Earlier NNMT knockdown research helped establish the enzyme as a metabolic target in adipose tissue and liver.
These are preclinical studies. Results in mice do not establish weight-loss efficacy, a human dose, long-term safety or a meaningful clinical outcome in people. Even route findings can differ across species and formulations. The mechanism is a reason for research, not a substitute for human evidence.
The distinction between target validation and product validation is important. Knocking down an enzyme genetically can help researchers understand its role, but it does not show that a small-molecule inhibitor will reproduce the same balance of effects. A compound can also engage unintended targets, distribute unevenly among tissues or produce metabolites that the genetic experiment never tested.
The later pharmacology work adds useful exposure information, yet it still does not create a human capsule protocol. Oral bioavailability, tissue distribution and metabolic effects in mice may translate incompletely or not at all. Promise includes the study because uncertainty should be inspectable, not because an animal result is a sales claim.
NNMT itself is expressed across tissues and participates in pathways that are not reducible to fat mass. Changing nicotinamide and methyl-donor handling may have downstream consequences that short preclinical studies cannot fully map. Long-term human safety is therefore an open question, not a blank space to fill with confidence.
If the capsule is confirmed and the draft is published, the visit would begin with a 5-Amino-1MQ-specific intake. It would cover metabolic history, current medicines and supplements, liver and kidney history, pregnancy status, cancer history, recent symptoms and the reason for the request.
A licensed provider would review both the chart and the unusually early state of the evidence. They could ask for more information, recommend a better-supported option, prescribe, or decline. Starting a visit never guarantees a prescription. If prescribed, a licensed U.S. compounding pharmacy would prepare and dispense the patient-specific capsules.
Pregnancy or breastfeeding, liver or kidney disease, active cancer, unexplained symptoms, and medicines or supplements aimed at metabolic or NAD+-related pathways require careful review. Because robust human safety data are not established, absence of a known contraindication is not the same as evidence of safety.
A provider may reasonably decline because the goal is better addressed with nutrition, movement, sleep, an approved treatment or evaluation for an underlying condition. That is especially important when someone is seeking an answer for rapid weight change, fatigue, glucose symptoms or abnormal liver tests.
The absence of a long public side-effect list should not be mistaken for reassurance. It mainly reflects the absence of mature human trials. The provider's job is to treat that missing information as uncertainty, explain it plainly and avoid inferring safety from silence.
The pending product is a compounded capsule. Its labeled strength is a product fact, not a public protocol, and animal-study schedules should never be converted into human dosing instructions. The provider sets any instructions and follow-up plan after evaluating the individual.
5-Amino-1MQ is interesting because NNMT connects several metabolic pathways and because researchers have developed direct inhibitors. It is uncertain because human outcome and safety evidence remain limited. Promise keeps both statements visible: do not call it a peptide, do not turn mouse findings into a promised benefit, and do not separate the prescription decision from a licensed provider.
5-Amino-1MQ is a small molecule, not a peptide. It is studied as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that uses nicotinamide and S-adenosylmethionine. Most direct evidence is preclinical, including cell and animal studies.
A real prescription if the pending capsule format is confirmed and the entry is published. A licensed provider would review your history, and a licensed U.S. pharmacy would compound it. It would not be a product labeled for laboratory use.
No. A licensed provider reviews every 5-Amino-1MQ request and prescribes only when it is appropriate for you. If it isn't, you'll be told plainly — that review is the point.
No. It is a small molecule designed to inhibit NNMT. Calling it a peptide is chemically incorrect and can blur the most important evidence distinction: direct studies are largely preclinical rather than established human peptide trials.
No. 5-Amino-1MQ is not FDA-approved. The compounded capsule described here would not be reviewed by the FDA for safety, effectiveness or quality.
You would complete a product-specific intake covering metabolic history, medicines and supplements, liver and kidney history, pregnancy status and the reason for the request. A licensed provider would review it and could prescribe, request more information or decline.
Because human safety evidence is limited, a provider carefully reviews pregnancy or breastfeeding, liver or kidney disease, metabolic conditions, active cancer and medicines or supplements aimed at the same pathways. The provider may decide the evidence is too early for the goal described.
5-Amino-1MQ sold without a prescription may be labeled for laboratory use and comes without human-use oversight, a provider or patient-specific dispensing. A Promise prescription would require all of those clinical safeguards.
Other Metabolic Support & Fat Loss options a provider may consider.
Metabolic Support & Fat Loss
Dual-action GLP-1 / GIP for weight management.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Metabolic Support & Fat Loss
GLP-1 support for appetite and weight goals.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Type a treatment, a goal, or a question.